FANDOM


Mazindol
Mazindol
Synonyms 42-548, AN-448, SaH-42548
Brand names Mazanor, Sanorex and Teronac
IUPAC name

IUPAC name
5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
ChemSpider

3880

DrugBank

DB00579

PubChem

4020

PDB fields

N/A

Formula

C16H13ClN2O

InChI
InChI
1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
InChIKey
InChIKey
ZPXSCAKFGYXMGA-UHFFFAOYSA-N
SMILES
SMILES
C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
(Jmol 3D structure)
Mol. mass

284.7402 g/mol

Mazindol is a stimulant of the tetracyclic class that is primarily used in the treatment of obesity. It was once marketed in Australia (introduced in 1970s, discontinued in 1993),[1][2][3][4] Canada, Germany, Ireland, South Africa, Singapore, Switzerland, the U.K. and the U.S. but has been withdrawn from these countries usually because of concerns over its potential for causing cardio/cerebro-vascular side effects like pulmonary arterial hypertension,[5] heart attacks and strokes. These concerns are largely ill-founded and rather centres on the fact that it is a stimulant and stimulants are generally no-longer recommended as a treatment for obesity in most countries.[6] It is still available in three developed countries: Greece, Hong Kong and Japan. 

External linksEdit

Reference listEdit

  1. "LETTERS TO THE EDITOR". Australian Prescriber 23 (6): 115–117. June 2000. ISSN 0312-8008. 
  2. Adverse Drug Reactions Advisory Committee, Office of Medicine Safety Monitoring (June 2005). "Genitourinary symptoms with reboxetine". Australian Adverse Drug Reactions Bulletin 24 (3). ISSN 0812-3837. 
  3. Montani, D; Seferian, A; Savale, L; Simonneau, G; Humbert, M (September 2013). "Drug-induced pulmonary arterial hypertension: a recent outbreak.". European Respiratory Review 22 (129): 244–50. PMID 23997051. doi:10.1183/09059180.00003313. 
  4. Ioannides-Demos, LL; Proietto, J; McNeil, JJ (2005). "Pharmacotherapy for obesity.". Drugs 65 (10): 1391–418. PMID 15977970. doi:10.2165/00003495-200565100-00006. 
  5. Montani, D; Seferian, A; Savale, L; Simonneau, G; Humbert, M (September 2013). "Drug-induced pulmonary arterial hypertension: a recent outbreak.". European Respiratory Review 22 (129): 244–50. PMID 23997051. doi:10.1183/09059180.00003313. 
  6. Brayfield, A, ed. (30 January 2013). "Mazindol". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 19 September 2014. 

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.